Smad4 Antibody (0.N.557): sc-73040
- Smad4 Antibody (0.N.557) is a mouse monoclonal IgG1 κ, cited in 4 publications, provided at 200 µg/ml
- raised against recombinant Smad4 of human origin
- recommended for detection of Smad4 of mouse, rat and human origin by WB, IP, IF and IHC(P)
- See Smad4 (B-8): sc-7966 for Smad4 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP is the preferred secondary detection reagent for Smad4 Antibody (0.N.557) for WB and IHC(P) applications. This reagent is now offered in a bundle with Smad4 Antibody (0.N.557) (see ordering information below).
Smad4 Antibody (0.N.557) is a mouse monoclonal IgG1 antibody that detects Smad4 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Smad4, also known as DPC4, plays a crucial role as a central mediator in the transforming growth factor-beta (TGFβ) and bone morphogenetic protein (BMP) signaling pathways, which are essential for regulating cellular processes such as proliferation, differentiation, and apoptosis. Anti-Smad4 antibody (0.N.557) enables detection of protein interactions with other Smad family members, facilitating the transcriptional regulation of target genes in response to TGFβ and BMP signals. These interactions are vital for maintaining normal cellular functions and tissue homeostasis, and dysregulation of Smad4 has been implicated in various diseases, including cancer. Smad4 monoclonal antibody (0.N.557) helps researchers effectively study Smad4 expression and function, providing insights into cellular signaling and potential therapeutic targets.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Smad4 Antibody (0.N.557) References:
- SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer. | Wang, Y., et al. 2021. Lab Invest. 101: 463-476. PMID: 33303972
- SMAD4 haploinsufficiency in small intestinal neuroendocrine tumors. | Hofving, T., et al. 2021. BMC Cancer. 21: 101. PMID: 33509126
- Consequences of Mutations and Abnormal Expression of SMAD4 in Tumors and T Cells. | Wan, R., et al. 2021. Onco Targets Ther. 14: 2531-2540. PMID: 33888990
- SMAD4 Inhibits Granulosa Cell Apoptosis via the miR-183-96-182 Cluster and FoxO1 Axis. | Yao, W., et al. 2022. Reprod Sci. 29: 1577-1585. PMID: 34287793
- SMAD4 mutations do not preclude epithelial-mesenchymal transition in colorectal cancer. | Frey, P., et al. 2022. Oncogene. 41: 824-837. PMID: 34857888
- SMAD4 TGF-β-independent function preconditions naive CD8+ T cells to prevent severe chronic intestinal inflammation. | Igalouzene, R., et al. 2022. J Clin Invest. 132: PMID: 35426367
- The loss of epithelial Smad4 drives immune evasion via CXCL1 while displaying vulnerability to combinatorial immunotherapy in gastric cancer. | An, HW., et al. 2022. Cell Rep. 41: 111878. PMID: 36577366
- Smad4-mediated angiogenesis facilitates the beiging of white adipose tissue in mice. | Wang, C., et al. 2023. iScience. 26: 106272. PMID: 36915676
- Loss of SETD2 aggravates colorectal cancer progression caused by SMAD4 deletion through the RAS/ERK signalling pathway. | Ma, C., et al. 2023. Clin Transl Med. 13: e1475. PMID: 37962020
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Smad4 Antibody (0.N.557) | sc-73040 | 200 µg/ml | $322.00 | |||
Smad4 Antibody (0.N.557): m-IgG Fc BP-HRP Bundle | sc-539442 | 200 µg Ab; 10 µg BP | $361.00 |